Clinical trial · Observational
Prospective Evaluation of the Treatment of Cancer Associated Superficial Venous
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Superficial venous thrombosis (SVT) is very common in clinical practice. What's more, around 15- 20% of SVTs occur in the context of cancer. Today, cancer patients are excluded from therapeutic trials for DVT. There is therefore no high-level evidence-based treatment recommendation for these patients. Recent data suggest that the course of cancer-associated DVT is similar to that of cancer-associated deep vein thrombosis (DVT). However, there are currently few prospective data on the evolution of cancer-associated DVT in relation to the treatment used. Due to the absence of clear recommendations of treatment in case of SVT associated with cancer the investigators will perform a prospective observational study to evaluate the efficacy of different regiment of anticoagulant treatment ordered in clinical practice.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Superficial Vein Thrombosis | — | UNRESOLVED | — |
| Venous Thrombosis | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- risk (in %) of recurrence of VTE
- timeFrame
- at 3-month follow-up
- description
- risk of recurrence of VTE at 3-month follow-up in patients with cancer-associated SVT.
Secondary outcomes (19)
- measure
- association (%) between initial treatment and the risk of SVT recurrence
- timeFrame
- at 3 months
- measure
- association (%) between initial treatment and the risk of SVT recurrence
- timeFrame
- at 6 months
- measure
- association (%) between initial treatment and the risk of SVT recurrence
- timeFrame
- at 12 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient over 18 * Patient affiliated to a social security scheme * Patient who understands French * Patient with superficial venous thrombosis of the lower and upper limbs confirmed by a Doppler ultrasound less than one month old. * Patient with active cancer: * Cancer treatment within the last 6 months, * Detectable tumor disease, cancer treatment within the last 6 months, ongoing hormone therapy for cancer, palliative cancer. * The patient has received potentially non-curative cancer treatment (notably palliative chemotherapy). * Progression shows that the cancer treatment was not curative (due to recurrence or progression under treatment) (particularly in the case of recurrence after surgery) Exclusion Criteria: * Patients under legal protection * Patients with concomitant pulmonary embolism * Patient with proximal or distal deep vein thrombosis * Patient treated with anticoagulant therapy for another indication * Patient with a contraindication to anticoagulation: Thrombocytopenia less than 30,000 elements/mm3, active bleeding or history of severe bleeding. * Patient opposed to participation in research
References
Publications (0)
Data not yet available